Lithuania: Medicaments Containing Hormones Market 2025

Medicaments Containing Hormones Market Size in Lithuania

The Lithuanian medicaments containing hormones market contracted markedly to $X in 2022, falling by X% against the previous year. Over the period under review, consumption recorded a slight decline. As a result, consumption reached the peak level of $X. From 2015 to 2022, the growth of the market remained at a lower figure.

Medicaments Containing Hormones Production in Lithuania

In value terms, medicaments containing hormones production totaled $X in 2022 estimated in export price. In general, production, however, showed a buoyant increase. The pace of growth appeared the most rapid in 2013 with an increase of X% against the previous year. Over the period under review, production attained the peak level at $X in 2016; however, from 2017 to 2022, production failed to regain momentum.

Medicaments Containing Hormones Exports

Exports from Lithuania

In 2022, shipments abroad of medicaments containing hormones but not antibiotics decreased by X% to X tons for the first time since 2019, thus ending a two-year rising trend. Overall, exports, however, continue to indicate strong growth. The pace of growth was the most pronounced in 2018 when exports increased by X%. Over the period under review, the exports reached the maximum at X tons in 2021, and then shrank markedly in the following year.

In value terms, medicaments containing hormones exports fell markedly to $X in 2022. Over the period under review, exports saw a perceptible contraction. The most prominent rate of growth was recorded in 2018 with an increase of X%. As a result, the exports attained the peak of $X. From 2019 to 2022, the growth of the exports remained at a lower figure.

Exports by Country

Germany (X tons), Latvia (X tons) and the Netherlands (X kg) were the main destinations of medicaments containing hormones exports from Lithuania, with a combined X% share of total exports. The UK and Belarus lagged somewhat behind, together accounting for a further X%.

From 2012 to 2022, the most notable rate of growth in terms of shipments, amongst the main countries of destination, was attained by the UK (with a CAGR of X%), while the other leaders experienced more modest paces of growth.

In value terms, Germany ($X) remains the key foreign market for medicaments containing hormones but not antibiotics exports from Lithuania, comprising X% of total exports. The second position in the ranking was held by the Netherlands ($X), with a X% share of total exports. It was followed by Latvia, with a X% share.

From 2012 to 2022, the average annual rate of growth in terms of value to Germany stood at X%. Exports to the other major destinations recorded the following average annual rates of exports growth: the Netherlands (X% per year) and Latvia (X% per year).

Export Prices by Country

The average medicaments containing hormones export price stood at $X per ton in 2022, declining by X% against the previous year. In general, the export price continues to indicate a abrupt descent. The pace of growth appeared the most rapid in 2014 an increase of X% against the previous year. As a result, the export price reached the peak level of $X per ton. From 2015 to 2022, the average export prices remained at a lower figure.

There were significant differences in the average prices for the major overseas markets. In 2022, amid the top suppliers, the country with the highest price was the Netherlands ($X per ton), while the average price for exports to Belarus ($X per ton) was amongst the lowest.

From 2012 to 2022, the most notable rate of growth in terms of prices was recorded for supplies to the Netherlands (X%), while the prices for the other major destinations experienced mixed trend patterns.

Medicaments Containing Hormones Imports

Imports into Lithuania

For the fourth year in a row, Lithuania recorded decline in purchases abroad of medicaments containing hormones but not antibiotics, which decreased by X% to X kg in 2022. In general, imports, however, recorded significant growth. The most prominent rate of growth was recorded in 2015 with an increase of X%. Over the period under review, imports hit record highs at X tons in 2018; however, from 2019 to 2022, imports failed to regain momentum.

In value terms, medicaments containing hormones imports reduced sharply to $X in 2022. Overall, imports, however, saw a significant increase. The pace of growth was the most pronounced in 2015 with an increase of X% against the previous year. Over the period under review, imports hit record highs at $X in 2021, and then contracted significantly in the following year.

Imports by Country

In 2022, Belgium (X kg) was the main supplier of medicaments containing hormones to Lithuania, with a X% share of total imports. It was followed by Estonia (X kg), with a X% share of total imports.

From 2012 to 2022, the average annual growth rate of volume from Belgium stood at X%.

In value terms, Belgium ($X) constituted the largest supplier of medicaments containing hormones but not antibiotics to Lithuania, comprising X% of total imports. The second position in the ranking was taken by Estonia ($X), with less than X% share of total imports.

From 2012 to 2022, the average annual rate of growth in terms of value from Belgium amounted to X%.

Import Prices by Country

In 2022, the average medicaments containing hormones import price amounted to $X per kg, picking up by X% against the previous year. In general, the import price enjoyed a significant expansion. As a result, import price attained the peak level and is likely to continue growth in the immediate term.

Prices varied noticeably by country of origin: amid the top importers, the country with the highest price was Belgium ($X per kg), while the price for Estonia amounted to $X per kg.

From 2012 to 2022, the most notable rate of growth in terms of prices was attained by Ireland (X%), while the prices for the other major suppliers experienced more modest paces of growth.

Source: IndexBox Platform